(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.28%.
Spero Therapeutics's revenue in 2025 is $48,576,000.On average, 3 Wall Street analysts forecast SPRO's revenue for 2025 to be $1,153,754,663, with the lowest SPRO revenue forecast at $1,108,509,382, and the highest SPRO revenue forecast at $1,187,688,624. On average, 3 Wall Street analysts forecast SPRO's revenue for 2026 to be $17,220,219, with the lowest SPRO revenue forecast at $16,544,916, and the highest SPRO revenue forecast at $17,726,696.
In 2027, SPRO is forecast to generate $63,140,802 in revenue, with the lowest revenue forecast at $60,664,693 and the highest revenue forecast at $64,997,885.